These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 36736341)
21. Prediction by genetic MATS of 4CMenB vaccine strain coverage of invasive meningococcal serogroup B isolates circulating in Taiwan between 2003 and 2020. Muzzi A; Lu M-C; Mori E; Biolchi A; Fu T; Serino L mSphere; 2024 Jun; 9(6):e0022024. PubMed ID: 38752729 [No Abstract] [Full Text] [Related]
22. Association of Use of a Meningococcus Group B Vaccine With Group B Invasive Meningococcal Disease Among Children in Portugal. Rodrigues FMP; Marlow R; Simões MJ; Danon L; Ladhani S; Finn A JAMA; 2020 Dec; 324(21):2187-2194. PubMed ID: 33258889 [TBL] [Abstract][Full Text] [Related]
23. Neisseria meningitidis serogroup B carriage by adolescents and young adults living in Milan, Italy: Prevalence of strains potentially covered by the presently available meningococcal B vaccines. Terranova L; Principi N; Bianchini S; Di Pietro G; Umbrello G; Madini B; Esposito S Hum Vaccin Immunother; 2018 May; 14(5):1070-1074. PubMed ID: 29584565 [TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease. Beck E; Klint J; Neine M; Garcia S; Meszaros K Value Health; 2021 Jan; 24(1):91-104. PubMed ID: 33431159 [TBL] [Abstract][Full Text] [Related]
25. A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB). Marshall GS; Abbing-Karahagopian V; Marshall HS; Cenci S; Conway JH; Occhipinti E; Bekkat-Berkani R; Banzhoff A; Sohn WY Expert Rev Vaccines; 2023; 22(1):530-544. PubMed ID: 37278390 [TBL] [Abstract][Full Text] [Related]
26. Genetic Diversity of Meningococcal Serogroup B Vaccine Antigens among Carriage Isolates Collected from Students at Three Universities in the United States, 2015-2016. Marjuki H; Chang HY; Topaz N; Whaley MJ; Vuong J; Chen A; Jenkins LT; Hu F; Schmink S; Retchless AC; Thomas JD; Acosta AM; McNamara LA; Soeters HM; Mbaeyi S; Wang X mBio; 2021 May; 12(3):. PubMed ID: 34006659 [TBL] [Abstract][Full Text] [Related]
27. Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children. Castilla J; García Cenoz M; Abad R; Sánchez-Cambronero L; Lorusso N; Izquierdo C; Cañellas Llabrés S; Roig J; Malvar A; González Carril F; Boone ALD; Pérez Martín J; Rodríguez Recio MJ; Galmés A; Caballero A; García Rojas A; Juanas F; Nieto M; Viloria Raymundo LJ; Martínez Ochoa E; Rivas AI; Castrillejo D; Moreno Pérez D; Martínez A; Borràs E; Sánchez Gómez A; Pastor E; Nartallo V; Arteagoitia JM; Álvarez-Fernández B; García Pina R; Fernández Arribas S; Vanrell J; García Hernández S; Mendoza RM; Méndez M; López-Tercero MM; Fernández-Rodríguez Á; Blanco Á; Carrillo de Albornoz FJ; Ruiz Olivares J; Ruiz-Montero R; Limia A; Navarro-Alonso JA; Vázquez JA; Barricarte A N Engl J Med; 2023 Feb; 388(5):427-438. PubMed ID: 36724329 [TBL] [Abstract][Full Text] [Related]
28. 4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation. Wang B; Giles L; Andraweera P; McMillan M; Almond S; Beazley R; Mitchell J; Ahoure M; Denehy E; Flood L; Marshall H J Infect; 2023 Aug; 87(2):95-102. PubMed ID: 37268223 [TBL] [Abstract][Full Text] [Related]
29. Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands. Freudenburg-de Graaf W; Knol MJ; van der Ende A Vaccine; 2020 Nov; 38(49):7850-7857. PubMed ID: 33097311 [TBL] [Abstract][Full Text] [Related]
30. The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public health. Ladhani SN; Campbell H; Parikh SR; Saliba V; Borrow R; Ramsay M J Infect; 2015 Dec; 71(6):611-4. PubMed ID: 26433141 [TBL] [Abstract][Full Text] [Related]
31. High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: Concordant predictions between MATS and genetic MATS. Tozer SJ; Smith HV; Whiley DM; Borrow R; Boccadifuoco G; Medini D; Serruto D; Giuliani MM; Stella M; De Paola R; Muzzi A; Pizza M; Sloots TP; Nissen MD Hum Vaccin Immunother; 2021 Sep; 17(9):3230-3238. PubMed ID: 33847225 [TBL] [Abstract][Full Text] [Related]
32. Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England. Ladhani SN; Andrews N; Parikh SR; Campbell H; White J; Edelstein M; Bai X; Lucidarme J; Borrow R; Ramsay ME N Engl J Med; 2020 Jan; 382(4):309-317. PubMed ID: 31971676 [TBL] [Abstract][Full Text] [Related]
33. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination. Martinón-Torres F; Banzhoff A; Azzari C; De Wals P; Marlow R; Marshall H; Pizza M; Rappuoli R; Bekkat-Berkani R J Infect; 2021 Jul; 83(1):17-26. PubMed ID: 33933528 [TBL] [Abstract][Full Text] [Related]
34. Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269. Stella M; Giuliani M; Biolchi A; Tomei S; De Paola R; Bai X; Borrow R; Lucidarme J; La Gaetana R; Toneatto D; Pizza M; Serino L; Mori E; Giuliani MM Hum Vaccin Immunother; 2020 Apr; 16(4):945-948. PubMed ID: 31770063 [TBL] [Abstract][Full Text] [Related]
35. Exploiting Real-Time Genomic Surveillance Data To Assess 4CMenB Meningococcal Vaccine Performance in Scotland, 2015 to 2022. Rodrigues CMC; MacDonald L; Ure R; Smith A; Cameron JC; Maiden MCJ mBio; 2023 Apr; 14(2):e0049923. PubMed ID: 37036356 [TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies. Marshall HS; Vesikari T; Richmond PC; Wysocki J; Szenborn L; Beeslaar J; Maguire JD; Balmer P; O'Neill R; Anderson AS; Prégaldien JL; Maansson R; Jiang HQ; Perez JL Lancet Infect Dis; 2023 Jan; 23(1):103-116. PubMed ID: 36087588 [TBL] [Abstract][Full Text] [Related]
37. Meningococcal Serogroup B Disease in Vaccinated Children. Soler-Garcia A; Fernández de Sevilla M; Abad R; Esteva C; Alsina L; Vázquez J; Muñoz-Almagro C; Noguera-Julian A J Pediatric Infect Dis Soc; 2020 Sep; 9(4):454-459. PubMed ID: 31634404 [TBL] [Abstract][Full Text] [Related]
38. First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak. McNamara LA; Shumate AM; Johnsen P; MacNeil JR; Patel M; Bhavsar T; Cohn AC; Dinitz-Sklar J; Duffy J; Finnie J; Garon D; Hary R; Hu F; Kamiya H; Kim HJ; Kolligian J; Neglia J; Oakley J; Wagner J; Wagner K; Wang X; Yu Y; Montana B; Tan C; Izzo R; Clark TA Pediatrics; 2015 May; 135(5):798-804. PubMed ID: 25917990 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules. Biolchi A; Tomei S; Santini L; Welsch JA; Toneatto D; Gaitatzis N; Bai X; Borrow R; Giuliani MM; Mori E; Pizza M Hum Vaccin Immunother; 2019; 15(3):725-731. PubMed ID: 30352000 [TBL] [Abstract][Full Text] [Related]
40. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. Snape MD; Saroey P; John TM; Robinson H; Kelly S; Gossger N; Yu LM; Wang H; Toneatto D; Dull PM; Pollard AJ CMAJ; 2013 Oct; 185(15):E715-24. PubMed ID: 24062178 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]